1177 Overzicht aandelen Sino Biopharmaceutical Limited, een investeringsholding, is actief als farmaceutisch conglomeraat voor onderzoek en ontwikkeling in de Volksrepubliek China. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Sino Biopharmaceutical Limited Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Sino Biopharmaceutical Historische aandelenkoersen Huidige aandelenkoers HK$3.21 52 Week Hoogtepunt HK$4.25 52 Week Laag HK$2.29 Bèta 0.69 1 maand verandering -5.03% 3 maanden verandering -4.46% 1 Jaar Verandering 1.26% 3 jaar verandering -41.10% 5 jaar verandering -56.93% Verandering sinds IPO 11,719.72%
Recent nieuws en updates
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Is Sino Biopharmaceutical (HKG:1177) A Risky Investment? Dec 08
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21 Meer updates bekijken
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Is Sino Biopharmaceutical (HKG:1177) A Risky Investment? Dec 08
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21
Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States Nov 14
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Oct 21
Key Executive recently sold HK$51m worth of stock Oct 07
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar Oct 02
First half 2024 earnings: EPS and revenues exceed analyst expectations Sep 28
Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO Sep 27
Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024 Sep 16
Upcoming dividend of HK$0.03 per share Sep 03
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly Sep 02
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma Aug 28
Consensus EPS estimates increase by 11% Aug 20
First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023) Aug 14 Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma Aug 01
Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024 Jul 31
Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule Jul 18
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Jul 16
Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet Jul 15
Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%? Jul 12
Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection Jun 25
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)" Jun 19 Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection
Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director Jun 06
Upcoming dividend of HK$0.03 per share Jun 04
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma May 24
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly May 21
Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China May 10
Full year 2023 earnings: EPS and revenues miss analyst expectations May 01
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules May 01
Investor sentiment improves as stock rises 18% Apr 26
Executive Chairwoman of the Board recently bought HK$5.8m worth of stock Apr 21
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings Apr 21
Consensus revenue estimates fall by 13% Apr 04
What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates Apr 03
Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024 Mar 29
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 29
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024 Mar 28
Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price Mar 20
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225" Mar 16
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet Mar 13
Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 02
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart Feb 28
Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion. Feb 08
Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553) Jan 23
Now 21% undervalued Jan 15
Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain Dec 28
Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma Dec 22
Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722 Dec 12
Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038 Dec 05
An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million. Nov 10
Investor sentiment improves as stock rises 16% Oct 30
Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug Oct 17 An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million. Oct 11
Upcoming dividend of HK$0.02 per share at 2.7% yield Sep 27
Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA Sep 26
First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022) Aug 26
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023 Aug 26
Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023 Aug 03
Key Executive recently bought HK$34m worth of stock Jul 04
Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms Jul 01
Upcoming dividend of HK$0.06 per share at 3.0% yield Jun 13
Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine May 24
Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection) May 11
Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock Apr 06
Full year 2022 earnings: EPS and revenues miss analyst expectations Apr 01
Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation Feb 11
Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer Jan 14
Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203" Dec 10
Less than half of directors are independent Nov 16 Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023
Investor sentiment improved over the past week Oct 18
Upcoming dividend of HK$0.06 per share Aug 30
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022 Aug 24
First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 24
Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022 Aug 12 Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022
Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule Jun 28
Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial Jun 15
Upcoming dividend of HK$0.04 per share Jun 08 Rendement voor aandeelhouders 1177 HK Pharmaceuticals HK Markt 7D -2.7% -3.3% -2.2% 1Y 1.3% -2.4% 18.3%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: 1177 overtrof de Hong Kong Pharmaceuticals industrie, die het afgelopen jaar een rendement -2.4 % opleverde.
Rendement versus markt: 1177 presteerde slechter dan Hong Kong Market , dat het afgelopen jaar een rendement van 18.3 % opleverde.
Prijsvolatiliteit Is 1177's price volatile compared to industry and market? 1177 volatility 1177 Average Weekly Movement 5.4% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.9% 10% most volatile stocks in HK Market 18.7% 10% least volatile stocks in HK Market 4.1%
Stabiele aandelenkoers: 1177 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van 1177 is het afgelopen jaar stabiel geweest.
Over het bedrijf Sino Biopharmaceutical Limited, een investeringsholding, is actief als farmaceutisch conglomeraat voor onderzoek en ontwikkeling in de Volksrepubliek China. Het is actief via drie segmenten: Gemoderniseerde Chinese Geneesmiddelen en Chemische Geneesmiddelen, Investeringen en Overige. Het bedrijf biedt oncologische geneesmiddelen aan, waaronder anlotinib hydrochloride capsules onder het merk Focus V, penpulimab injectie onder het merk Annike, efbemalenograstin alfa injectie onder het merk Yilishu, pomalidomide capsules onder het merk Anyue, bevacizumab injectie onder het merk Anbeisi, rituximab injectie onder het merk Delituo en trastuzumab voor injectie onder het merk Saituo; geneesmiddelen tegen leveraandoeningen, zoals magnesiumisoglycyrrhizinaatinjectie onder het merk Tianqing Ganmei en entecavir dispergeerbare tabletten onder het merk Runzhong; en geneesmiddelen voor het ademhalingssysteem, waaronder budesonidesuspensie voor inhalatie onder het merk Tianqing suchang en colistimethaatnatrium voor injectie onder het merk Tianyun.
Meer tonen Sino Biopharmaceutical Limited Samenvatting Hoe verhouden de winst en inkomsten van Sino Biopharmaceutical zich tot de beurswaarde? 1177 fundamentele statistieken Marktkapitalisatie HK$58.44b Inkomsten(TTM ) HK$2.28b Inkomsten(TTM ) HK$29.59b
25.6x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) 1177 resultatenrekening (TTM ) Inkomsten CN¥27.79b Kosten van inkomsten CN¥5.23b Brutowinst CN¥22.56b Overige uitgaven CN¥20.41b Inkomsten CN¥2.14b
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) 0.12 Brutomarge 81.16% Nettowinstmarge 7.71% Schuld/Eigen Vermogen Verhouding 22.6%
Hoe presteerde 1177 op de lange termijn?
Bekijk historische prestaties en vergelijking Dividenden
1.8% Huidig dividendrendement
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2024/12/20 23:06 Aandelenkoers aan het einde van de dag 2024/12/20 00:00 Inkomsten 2024/06/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Sino Biopharmaceutical Limited wordt gevolgd door 51 analisten. 23 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Justin Liu BNP Paribas Securities (Asia) Ling Zhang BNP Paribas Securities (Asia) Wai Chak Yuen BOCI Research Ltd.
Toon 48 meer analisten 
